Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DPP4 | P27487 | 20/20 | 1.00 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.63 |
| ▸ | FAP | Q12884 | 1/20 | 0.63 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2020371 | 1.00 | DPP4 (1.00) | DPP4KCNH2FAP | |
| Benzoic Acid SCHEMBL28645610 | 0.92 | DPP4 (1.00) | DPP4KCNH2FAP | |
| SCHEMBL2024039 | 0.87 | DPP4 (0.77) | DPP4FAP | |
| SCHEMBL2023363 | 0.87 | DPP4 (0.77) | DPP4 | |
| SCHEMBL2024037 | 0.87 | DPP4 (0.77) | DPP4FAP | |
| SCHEMBL2023360 | 0.87 | DPP4 (0.77) | DPP4 | |
| SCHEMBL2027764 | 0.87 | DPP4 (0.78) | DPP4 | |
| SCHEMBL2027763 | 0.87 | DPP4 (0.78) | DPP4 | |
| SCHEMBL28636345 | 0.87 | DPP4 (0.76) | DPP4KCNH2FAP | |
| SCHEMBL2201273 | 0.86 | DPP4 (0.76) | DPP4KCNH2FAP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2521721-B1 | 3-(3-AMINOPIPERIDIN-1-YL)-5-OXO-1,2,4-TRIAZINE DERIVATES AS DIPEPTIDYL PEPTIDASE IV(DPP-IV) INHIBITORS | SHANGHAI FOCHON PHARMACEUTICAL CO LTD (CN) | 2014-10-01 | — | — | EP | claimed |
| US-8648073-B2 | Certain dipeptidyl peptidase inhibitors | FOCHON PHARMA, INC. (US) | 2014-02-11 | — | — | US | claimed |
| EP-2521721-A1 | 3-(3-AMINOPIPERIDIN-1-YL)-5-OXO-1,2,4-TRIAZINE DERIVATES AS DIPEPTIDYL PEPTIDASE IV(DPP-IV) INHIBITORS | Shanghai Fochon Pharmaceutical Co. Ltd (CN) | 2012-11-14 | — | — | EP | claimed |
| WO-2011079778-A1 | 3-(3-AMINOPIPERIDIN-1-YL)-5-OXO-1,2,4-TRIAZINE DERIVATES AS DIPEPTIDYL PEPTIDASE IV(DPP-IV) INHIBITORS | CHINA SHANGHAI FOCHON PHARMACEUTICAL CO LTD (CN) | 2011-07-07 | — | — | WO | claimed |
| CN-115246817-B | Crystal form beta of compound A benzoate, preparation method thereof and pharmaceutical composition containing crystal form beta | 深圳信立泰药业股份有限公司 | 2024-06-18 | — | — | CN | disclosed |
| US-20240115577-A1 | SMALL MOLECULE REGULATORS OF ALVEOLAR TYPE 2 CELL PROLIFERATION FOR THE TREATMENT OF PULMONARY DISEASES | THE SCRIPPS RESEARCH INSTITUTE | 2024-04-11 | — | — | US | disclosed |
| CN-113493435-B | Amorphous compound A benzoate, preparation method thereof and pharmaceutical composition containing amorphous compound A benzoate | 深圳信立泰药业股份有限公司 | 2024-01-26 | — | — | CN | disclosed |
| CN-115246817-A | Crystal form beta of compound A benzoate, preparation method thereof and pharmaceutical composition containing crystal form | 深圳信立泰药业股份有限公司 | 2022-10-28 | — | — | CN | disclosed |
| CN-106349215-B | Amorphous form of compound A benzoate, preparation method thereof and pharmaceutical composition containing amorphous form | 深圳信立泰药业股份有限公司 | 2022-02-08 | — | — | CN | disclosed |
| CN-104803971-B | Crystal form alpha of compound A mono benzoate, preparation method thereof and pharmaceutical composition containing crystal form | 深圳信立泰药业股份有限公司 | 2021-11-30 | — | — | CN | disclosed |
| CN-113493435-A | Amorphous form of compound A benzoate, preparation method thereof and pharmaceutical composition containing amorphous form | 深圳信立泰药业股份有限公司 | 2021-10-12 | — | — | CN | disclosed |
| CN-106349216-B | Crystal form alpha of compound A, preparation method thereof and pharmaceutical composition containing crystal form | 深圳信立泰药业股份有限公司 | 2020-09-11 | — | — | CN | disclosed |
| US-9340523-B2 | Certain dipeptidyl peptidase inhibitors | FOCHON PHARMA, INC. (US) | 2016-05-17 | — | — | US | disclosed |
| EP-2521721-B1 | 3-(3-AMINOPIPERIDIN-1-YL)-5-OXO-1,2,4-TRIAZINE DERIVATES AS DIPEPTIDYL PEPTIDASE IV(DPP-IV) INHIBITORS | SHANGHAI FOCHON PHARMACEUTICAL CO LTD (CN) | 2014-10-01 | — | — | EP | disclosed |
| US-20140213590-A1 | CERTAIN DIPEPTIDYL PEPTIDASE INHIBITORS | FOCHON PHARMA, INC. (US) | 2014-07-31 | — | — | US | disclosed |
| US-8648073-B2 | Certain dipeptidyl peptidase inhibitors | FOCHON PHARMA, INC. (US) | 2014-02-11 | — | — | US | disclosed |
| EP-2521721-A1 | 3-(3-AMINOPIPERIDIN-1-YL)-5-OXO-1,2,4-TRIAZINE DERIVATES AS DIPEPTIDYL PEPTIDASE IV(DPP-IV) INHIBITORS | Shanghai Fochon Pharmaceutical Co. Ltd (CN) | 2012-11-14 | — | — | EP | disclosed |
| WO-2011079778-A1 | 3-(3-AMINOPIPERIDIN-1-YL)-5-OXO-1,2,4-TRIAZINE DERIVATES AS DIPEPTIDYL PEPTIDASE IV(DPP-IV) INHIBITORS | CHINA SHANGHAI FOCHON PHARMACEUTICAL CO LTD (CN) | 2011-07-07 | — | — | WO | disclosed |
| US-20110160212-A1 | CERTAIN DIPEPTIDYL PEPTIDASE INHIBITORS | FOCHON PHARMA, INC. | 2011-06-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110160212-A1 | CERTAIN DIPEPTIDYL PEPTIDASE INHIBITORS | DPP4, DPP3, DPP8 | DPP4 1/4885KCNH2 4352/4885FAP 9/4885 |
| US-20140213590-A1 | CERTAIN DIPEPTIDYL PEPTIDASE INHIBITORS | DPP4, DPP3, DPP8 | DPP4 1/4885KCNH2 4352/4885FAP 9/4885 |
| US-20240115577-A1 | SMALL MOLECULE REGULATORS OF ALVEOLAR TYPE 2 CELL PROLIFERATION FOR THE TREATMENT OF PULMONARY DISEASES | DPP4, DPP7, ING2 | DPP4 1/4885KCNH2 4421/4885FAP 850/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.